PRME$3.32
Chart
Performance
Key Stats
AI PRME Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyPrime Medicine Inc. demonstrates strong potential in the gene editing therapeutic space, supported by a solid balance sheet and promising technological advancements. However, it is still in an early growth phase with no revenue and significant cash burn, and its current stock price reflects high growth expectations.
Thematic
Prime Medicine is at the forefront of gene editing therapies, a rapidly expanding and transformative field. The company's proprietary Prime Editing technology offers a unique advantage in addressing a broad range of genetic diseases.
Fundamental
Prime Medicine possesses a strong balance sheet with substantial cash reserves, providing ample runway for its R&D efforts. However, the company is pre-revenue and exhibits significant operating losses, typical for its stage of development.
Technical
The stock has experienced significant volatility. While it has seen upward momentum in the past month, it is currently trading below its 50-day and 200-day moving averages, suggesting a lack of sustained positive trend.
| Factor | Score |
|---|---|
| Gene Editing Technology Advancement | 95 |
| Untapped Market Potential | 90 |
| Biotechnology Innovation | 80 |
| Competitive Landscape | 75 |
| Regulatory Approval Pathway | 70 |
| Factor | Score |
|---|---|
| Valuation | 40 |
| Profitability | 10 |
| Growth | 0 |
| Balance Sheet Health | 90 |
| Cash Flow | 20 |
| Debt Level | 85 |
| Factor | Score |
|---|---|
| Trend Analysis | 30 |
| Momentum | 60 |
| Volume Confirmation | 70 |
| Support & Resistance | 50 |
| Recent Performance | 70 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Positive Recent Performance
The stock has shown strong recent performance, with a 1-month return of 74.59% and a Year-to-Date (YTD) return of 41.30%. This indicates significant positive momentum.
Sufficient Cash Reserves
The company has substantial cash and cash equivalents (e.g., $182.48M in Q4 2024, $41.57M in Q4 2023, $187.62M in Q4 2022), which can support operations, R&D, and buffer against unforeseen challenges.
Bearish Points (8)
High Price-to-Sales Ratio
The Price-to-Sales (PS) ratio is extremely high (e.g., 147.9x TTM, 184.1x for Q1 2025), indicating that the current market valuation is not supported by current sales revenue, suggesting high expectations for future growth.
Significant Net Losses
The company is experiencing substantial net losses (e.g., -$195.88M in 2024, -$198.13M in 2023) and negative EPS (-$1.61 TTM), indicating it is not yet profitable.
Calendar
August 2025
7
Next Earnings Date
H: $-0.26
A: $-0.34
L: $-0.42
H: 15.00M
A: 3.00M
0Profile
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic therapies to address the spectrum of diseases by deploying gene editing technology in the United States. It offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Seasonals
Price Target
7.36 USD
The 39 analysts offering 1 year price forecasts for PRME have a max estimate of 12.00 and a min estimate of 1.50.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Direct competitor in high-performance computing, GPUs, and CPUs. Both companies are vying for market share in the AI and data center segments.
Weight: 88
Major competitor in CPUs and expanding into discrete GPUs and AI accelerators. Intel's foundry services also represent a potential future partner or competitor.
Weight: 90
Key foundry partner for NVIDIA's chip manufacturing. Their technological advancements and production capacity directly impact NVIDIA's supply and innovation.
Weight: 75
Critical supplier of lithography equipment to chip manufacturers like TSMC, which in turn impacts NVIDIA's ability to produce advanced chips.